Pillar 1 - FTO (new thread), page-2364

Havent been following the story for a while. With management and board changes and cardio protection a now a big focus the FTO inhibition story is less visible to me. Can i tempt anyone to explain whether the lab/clinical trial process remains on track. Melanoma was an early target. As a bit of a tease: when i first started looking at this stock it showed promise as a cancer treatment of equal standing to standard of care in some setting but noted as being less damaging to heart. then that got de-emphasised as the FTO discovery took centre stage. Now the focus is cardio protection which feels more like the original story. I understand that cardio-protection could have broad application. But before cardio protection Wombat et al were talking about a drug that was bigger than Keytruda. Has the FTO opportunity been downgarded, pushed out delayed, seem less likely of scusses then a year ago. Has anything changed?